Suproclone
 | |
| Systematic (IUPAC) name | |
|---|---|
| [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7- dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl]-4-propanoylpiperazine-1-carboxylate | |
| Clinical data | |
| Identifiers | |
77590-92-2  | |
| None | |
| PubChem | CID 53696 |
| ChemSpider |
48481  |
| UNII |
J4AM5D708G |
| KEGG |
D05975 |
| Chemical data | |
| Formula | C22H22ClN5O4S2 |
| 520.024 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Suproclone is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc.[1] Other cyclopyrrolone drugs include zopiclone, pagoclone and suriclone.
Suproclone is very similar in structure to the related drug suriclone, but little information has been published about it specifically. However it can be expected that the mechanism of action by which suproclone produces its sedative and anxiolytic effects is by modulating benzodiazepine receptors (resulting in an increased response to endogenous GABA), in a similar manner to other drugs of this class.[2][3]
References
- ↑ Psychotropics.dk. "suproclone". Retrieved 24 August 2009.
- ↑ Colin R. Gardner. Pharmacological profiles in vivo of benzodiazepine receptor ligands. Drug Development Research 1988. 12(1):1-28.
- ↑ Ian L. Martin, Adam Doble, David J. Nutt. Calming the Brain: Benzodiazepines and Related Drugs from Laboratory to Clinic. Informa Healthcare (October 24, 2003). ISBN 1-84184-052-1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||